First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04711161 |
|
Recruitment Status :
Recruiting
First Posted : January 15, 2021
Last Update Posted : February 28, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel.
Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a salt-inducible kinase inhibitor, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of dose limiting toxicities (DLTs) or adverse events.
Part 2 (Phase IB) will test the tolerability of continuous 28-day cycles of GRN-300 in combination with weekly paclitaxel given 3 of 4 weeks per month (x 3).
Overall duration of the study will be approximately 48 months, depending on the rate of enrollment and number of subjects enrolled.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Tumors | Drug: GRN-300 Drug: Paclitaxel | Phase 1 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 73 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | GRN-300 single-agent and in combination with paclitaxel. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. |
| Actual Study Start Date : | December 21, 2020 |
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | March 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part 1 (Phase 1a): Single Arm, Open Label (GRN-300 single-agent)
Part 1 of the study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 as a single agent will be determined. The overall duration of Part 1 will be approximately 24-36 months, depending on the rate of enrollment and the number of subjects enrolled.
|
Drug: GRN-300
A salt-inducible kinase (SIK) inhibitor
Other Name: SIK2/3 Inhibitor |
|
Experimental: Part 2 (Phase 1b): Single Arm, Open Label (GRN-300 plus paclitaxel)
The study will determine the safety of continuous twice a day oral dosing of GRN-300, with each cycle consisting of 28 days of treatment, in combination with intravenously administered paclitaxel weekly x 3 during each 28-day cycle. The number of administered cycles will depend on the tolerability of each dose level and the severity and occurrence of side effects and DLTs. The maximal tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of GRN-300 in combination with paclitaxel will be determined. The overall duration of Part 2 will be approximately 12-18 months, depending on the rate of enrollment and the number of subjects enrolled. Part 2 will commence following determination of the MTD and RP2D of single-agent GRN-300 in Part 1. Overall duration of the study will be approximately 36-48 months, depending on the rate of enrollment and number of subjects enrolled. |
Drug: GRN-300
A salt-inducible kinase (SIK) inhibitor
Other Name: SIK2/3 Inhibitor Drug: Paclitaxel Microtubule inhibitor
Other Name: Taxane |
- Part 1 (Phase 1A) - Determination of the MTD and the RP2D of GRN-300 single-agent based on evaluation of the DLT in the study population. [ Time Frame: 24 months ]• Determination of the recommended Phase II dose (RP2D) of GRN-300 in the study population.
- Part 1 (Phase 1A) - Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. [ Time Frame: 24 months ]• To investigate the safety of repeated 28-day cycles of daily oral GRN-300 therapy in subjects with recurrent or metastatic ovarian, fallopian tube, and primary peritoneal cancer or other advanced solid tumors, based on the number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
- Part 2 (Phase 1B) - Determination of the MTD and the RP2D of GRN-300 with paclitaxel based on evaluation of the DLT in the study population [ Time Frame: 24 months ]• Determination of the recommended Phase II dose (RP2D) of GRN-300 in combination with weekly paclitaxel in the study population.
- Part 2 (Phase 1B) - Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. [ Time Frame: 24 months ]• To investigate the safety of repeated 28-day cycles of daily oral GRN-300 therapy in combination with weekly paclitaxel x 3 in subjects with recurrent or metastatic ovarian, fallopian tube, and primary peritoneal cancer or other advanced solid tumors, based on the number of participants with treatment-related adverse events as assessed by CTCAE v5.0.
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (Cmax). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Maximum plasma concentration (Cmax)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (tmax). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Time to Cmax (tmax)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (t1/2). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Terminal half-life (t1/2)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (AUC0-t). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Area under the plasma concentration-time curve from zero to the last measurable concentration (AUC0-t)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (AUC0-Inf). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Area under the plasma concentration-time curve from zero to infinity (AUC0-Inf)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (CL/F). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Apparent oral clearance (CL/F)
- Part 1 (Phase 1A) - Determination of GRN-300 monotherapy PK profile (Vz/F). [ Time Frame: 24 months ]
• To evaluate the pharmacokinetic (PK) profile of GRN-300 after oral administration of a single dose and at steady state.
- Apparent volume of distribution during terminal distribution phase (Vz/F)
- Part 1 (Phase 1A) - Estimation of the clinical activity of single agent GRN-300 (ORR) [ Time Frame: 24 months ]• Overall response rate (ORR) per investigator assessment using RECIST v1.1 defined as the percentage of subjects having a best overall response (BOR) of complete response (CR) or partial response (PR)
- Part 1 (Phase 1A) - Estimation of the clinical activity of single agent GRN-300 (DCR) [ Time Frame: 24 months ]• Disease control rate (DCR) per investigator assessment using RECIST v1.1 defined as the percentage of subjects having a BOR of CR, PR, or stable disease (SD) ≥ 4 months (4 cycles, 28 days each)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (Cmax). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Maximum plasma concentration (Cmax)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (tmax). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Time to Cmax (tmax)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (t1/2). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Terminal half-life (t1/2)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (AUC0-t). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Area under the plasma concentration-time curve from zero to the last measurable concentration (AUC0-t)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (AUC0-Inf). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Area under the plasma concentration time curve from zero to infinity (AUC0-Inf)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (CL/F). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Apparent oral clearance (CL/F)
- Part 2 (Phase 1B) - Determination of GRN-300 plus paclitaxel PK profile (Vz/F). [ Time Frame: 24 months ]
• To evaluate the PK profile of GRN-300 and paclitaxel following administration of a single dose of each and at steady state.
- Apparent volume of distribution during terminal distribution phase (Vz/F)
- Part 2 (Phase 1B) - Estimation of the clinical activity of GRN-300 plus paclitaxel (ORR). [ Time Frame: 24 months ]• Overall response rate (ORR) per investigator assessment using RECIST v1.1 defined as the percentage of subjects having a best overall response (BOR) of complete response (CR) or partial response (PR)
- Part 2 (Phase 1B) - Estimation of the clinical activity of GRN-300 plus paclitaxel (DCR). [ Time Frame: 24 months ]• DCR per investigator assessment using RECIST v.1.1 defined as the percentage of subjects having a BOR of CR, PR, or SD ≥ 4 months (4 cycles, 28 days each)
- Part 1 and 2: progression free survival (PFS) [ Time Frame: 48 months ]• To estimate progression free survival (PFS) per investigator assessment using RECIST v1.1 for subjects who received continuous GRN-300 single-agent or in combination with weekly paclitaxel x 3
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years.
- Part 1 dose-escalation cohorts: Diagnosis of persistent or recurrent, locally non-resectable or metastatic ovarian, primary peritoneal or fallopian tube epithelial cancer, or advanced solid tumors of any other histology who have progressed on standard therapy and for whom no further effective therapy is available
- Part 1 dose-expansion cohort / Part 2 dose-escalation cohorts / Part 2 dose-expansion cohort: Diagnosis of persistent or recurrent, locally non-resectable or metastatic ovarian, primary peritoneal or fallopian tube epithelial cancer who have progressed on standard therapy and for whom no further effective therapy is available. Patients with advanced solid tumors of any other histology will not be eligible to be enrolled in these cohorts.
- Part 2 dose-escalation cohorts / Part 2 dose-expansion cohort: paclitaxel treatment for the tumor should be indicated
- Histologic or cytologic confirmation of the original tumor by Pathology assessment is required.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension, as defined by RECIST 1.1.
- Prior therapy: Patients must have received at least one prior second-line treatment for persistent, recurrent, locally non-resectable or metastatic disease but may have received any number of prior treatments.
- Any unresolved toxicities from prior therapy should be no greater than NCI-CTCAE v5.0 Grade 1 at screening.
- Patients who are expected to survive a minimum of three months after the first administration of the study drug.
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-1.
- Adequate bone marrow, liver and renal function.
Exclusion Criteria:
- Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug.
- Patients with known hypersensitivity to paclitaxel excluded from Part 2 paclitaxel combination only).
- Use of any cytotoxic chemotherapy or investigational drugs, biologics, or devices within 21 days prior to study enrollment.
- Women who are pregnant or breastfeeding.
- Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
- Known CNS metastases or leptomeningeal disease.
- Gastrointestinal dysfunction that may affect oral drug absorption (e.g., intermittent or chronic bowel obstruction, short gut, etc.).
- Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within six months of start of study treatment.
- Other medical co-morbidities that in the investigator's judgment would increase the risks of participation
- QTc >480 msec be excluded from the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04711161
| Contact: Markus Peter, PhD, MBA | 908-873-4963 | markus.peter@greenfirebio.com | |
| Contact: Clinical Operations | GRN300-001.operations@greenfirebio.com |
| United States, Texas | |
| MD Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Siqing Fu, MD, PhD 713-792-4318 siqingfu@mdanderson.org | |
| Contact: Katherine Torres (832)750-4997 ktorres4@mdanderson.org | |
| Sub-Investigator: Robert C. Bast, MD | |
| Sub-Investigator: Amir A. Jazaeri, MD | |
| Principal Investigator: | Siqing Fu, MD, PhD | M.D. Anderson Cancer Center |
| Responsible Party: | Green3Bio, Inc. |
| ClinicalTrials.gov Identifier: | NCT04711161 |
| Other Study ID Numbers: |
GRN300-001 |
| First Posted: | January 15, 2021 Key Record Dates |
| Last Update Posted: | February 28, 2023 |
| Last Verified: | February 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Fallopian Tube Neoplasms Ovarian Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Fallopian Tube Diseases Adnexal Diseases Endocrine Gland Neoplasms Ovarian Diseases |
Endocrine System Diseases Gonadal Disorders Paclitaxel Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |